PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/21393 Please be advised that this information was generated on 2015-01-24 and may be subject to change. 656 CORRESPONDENCE of less than 6- 5 mg per kg) is currently the drug of first choice.“ If these measures fail, a wide variety of other medications have been advocated. These include thalidomide,3 dapsone, oral gold,5 alpha interferon,6 and retinoids/ All have been shown, in at least one study, to produce a good clinical response in patients with DLE who have failed to respond to the combination of topical steroids, sunblocks and hydroxychlor oquine. However, in our experience, we have encountered a number of patients with active DLE who have failed to respond to the above treatments. In addition, the toxicity of some treatments, such as thalidomide, oral gold or retinoids, may limit their use. We were therefore interested to assess the potential use of MTX in the management of DLE, which has not been reported previously, and which might be a useful addition to the therapeutic armamentarium for this condition. Low-dose weekly oral MTX is a relatively safe drug and hepatotoxicity is usually limited to psoriatics whose condition is complicated by a secondary factor such as alcohol excess, diabetes mellitus, arsenic ingestion, or obesity. The American Rheumatism Association does not recommend routine pre treatment liver biopsy for patients with uncomplicated rheumatoid arthritis receiving MTX,8 as very few problems have been reported with its use in this condition. Side-effects reported in patients with SLE have included neutropenia and oral ulceration, and have tended to be confined to those patients with active disease with renal impairment. Thus, short-term treatment of DLE with MTX is most unlikely to be complicated by any significant side-effects, in the absence of an additional factor. Possible mechanisms of action of MTX in DLE might include inhibition of T-cell activation and the inhibition of migration of inflammatory cells into the affected area. As only a small number of patients were included in this study, the conclusions drawn must be limited. However, the reasonable response seen in two of the four patients suggests that MTX may be of help in patients with therapy-resistant DLE which has failed to respond to hydroxychloroquine, and in whom other treatments, such as thalidomide, oral gold or retinoids, have either failed or are contraindicated. 1 Department of Der Leeds General Infirmary, Great George Street, Leeds LSI SEX, U.K. W.W.BorroMLKY M.J.D.Gooin'iiiU) 1 Rothenberg RJ, Graziano FM, Orandone JT el til. The use of methotrexate in steroid-resistant SLE. Arthritis Rheum 1988; 31: 6 1 2 -1 5 . 2 Goodlìeld MJ, Rowell NR. Connective tissue diseases. In: Textbook of Dermatology (Champion RH, Burton JL, libìing FJG, eds), 5th edn. Vol. 3. Oxford: Blackwell Scientific Publications, 1992; 2 1 8 4 -5 . 3 Knop J, Bonomann G, Ilapple R et a l Thalidomide in the treatm ent of 60 cases of chronic discoid lupus erythematosus. Hr J Dermatol 1983; 108: 4 6 1 - 6 . 4 Lindskov R, Reumann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 1968; 172: 2 1 4 -1 7 . 5 Dalziel K, Going G, Cartwright PH et al. Treatment of chronic discoid lupus erythematosous w ith oral gold compound (aurauofin). Hr ƒ : 115: 2 1 1 - 3 6. Der 6 Thiovelt J, Nicolas JF, Kanitakis ] et al. Recombinant interferon a 2 a is effective in the treatm ent of discoid and subacute cutaneous lupus erythematosus. Br J Dermatol 1990; 122: 405-9. 7 Shonick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus, J Am Acad Dermatol 1986; 14: 4 9 -5 2 . 8 Health and public policy committee, American College of Physi cians. Methotrexate in rheum atoid arthritis. Ann Intern Med 1987; 1 0 7 :4 1 8 - 1 9 . T r a n s g lu ta m in a s e -p o s itiv e c e lls in p so ria tic ep id erm is d u r in g tr e a tm e n t w ith calcitriol ( l o t , 2 5 d ih y d r o x y v ita m in D j ) a n d tacalcitol ( l a , 2 4 d ih y d r o x y v ita m in D ?) S ir , T h e keratinization process in human epidermis involves the formation of an insoluble cross-linked protein envelope. Involucrln, filaggrin and other major precursor proteins of the corniiied cell envelope are expressed late during epidermal differentiation.1 Involucrin expression starts in the upper spinous cell layers in normal human skin. Filaggrin expression is restricted to the granular layer and the stratum corneum.3 These and other precursor proteins become crosslinked by the activity of transglutaminase K, the rate limiting enzyme in the formation of the corniiied envelope, via e-(7 ~ glutamyl) lysine isopeptide bonds.4 It has been demonstrated that membrane-associated transglutaminase activity and the number of cross-linked envelopes are markedly increased in psoriatic skin. It is also well established that in psoriatic epidermis involucrin expres sion is significantly increased, whereas filaggrin expression is decreased or even absent. In keratinocytes in vitro, it has been demonstrated that corniiied envelope formation and transglutaminase activity are enhanced by calcitriol (la-,25 dihydroxy vitamin I)(). tacalcitol (Irv,24 dihydroxy vitamin Dj), and calcipotriol.'l) that In ,2 5 we repoi j D i and I n ,24 (OI'DiDj reduce the expression of involucrin and increase filaggrin expression in psoriatic skin.(>’10 A mouse monoclonal antibody (Igt52a) against human keratinocyte transglutaminase (BTT) has become available for tI I! j |* i ,ec e. the present investigation was to examine the effect of l« ,2 5 2 D) and of l a , 24 (Oil)_> l)5 on the expression of human keratinocyte transglutaminase in vivo during treatment of psoriatic plaques with these, derivatives. Twenty patients with stable psoriasis vulgaris were included in this study. Ten patients were treated with calcitriol in petrolatum (3 /¿g/g) twice daily. Before treatment, and after I , 2 and 4 weeks of treatment, punch biopsies ( J rnm) were taken from the psoriatic lesions. Calcitriol was obtained from Solvay Duphar, Amsterdam, the Netherlands. The other 10 patients were Ire; once daily on one half of the body, and the ointment base alone on the other half, for 8 weeks. Before treatment, and after 8 weeks of treatment, punch biopsies (3 mm) were taken from both body halves. To visualize transglutaminase type 1, which is expressed during differentiation of the epidermis, we used immuno* (<"> 1995 British Association of Dermutologists, British Journal o f D enm tologu, 1 33, 65 5 -6 6 0 >/c 0 80 70 60 50 40 30 20 10 0 Wk 0 Wk 4 Wk 4 Wk 0 Interpapillary Tip Figure 1. Plasma m em brane-bound transglutam inase before treat ment, and after 4 weeks of treatm ent with calcitrici 3 petrolatum, twice daily (n = 10). Mean ± standard error of the mean, peroxidase staining glut a m in a se (m o u se an anti-human keratinocyte trans is m was glutaminase expression was assessed by calculating the ratio positive cell layers/total cell layers of the living epidermis. This procedure was performed at two sites: at: the tip of a dermal papilla, and in the interpapillary region. On every slide, two representative areas were examined, and the mean of these observations was assessed. The Wilcoxon ranking test for matched pairs was used for statistical analysis. The calcitriol-treated lesions showed a statistically signifi cant reduction of transglutaminase expression at the tip of a dermal papilla after 4 weeks of treatment (P < 0*03). ary region, the transgluti tendency to decrease after 4 weeks (P < 0-075). The tacalcitol-treated lesions also showed a statistically significant decrease of transglutaminase expression at the tip of a dermal papilla (P < 0*03), whereas the expression in the interpapillary zone was not significantly a fleeted by treatment ( P < 0*125). The transglutaminase expression in the biopsies of the lesions treated with placebo did not change 0*2 in both areas). Figures 1 and 2 (I demonstrate the mean values ± the standard error of the mean. Figure 3 shows the distribution of transglutaminase before and after 4 weeks of treatment with calcitriol. It has been demonstrated that membrane-associated transglutaminase activity and the number of cross-linked envelopes are markedly increased in psoriatic skin and tenfold, respectively.5 Recently, we demonstrated by immunohistoehemistry that the number of transglutaminasepositive cells is markedly increased in lesional skin compared with the clinically uninvolved skin of psoriatic patients. The distribution pattern of transglutaminase comprised relatively more cell layers compared with the distribution pattern of involucrin. To date, the trigger for transglutaminase in psoriatic skin has still to be Identified. It is at involucrin expression stimulates the expression of its cross-linking enzyme directly. Alternatively, (a) (b) 100 ao 60 % 40 Figure 2. Plasma m em brane-bound transglutaminase before treatm ent, and after 8 weeks of treatm ent with tacaleitol ointm ent (4/tg/g) once daily and placebo ointm ent once daily (n = 10). Mean ± standard error of the mean, (a) Suprapapillary distribution pattern, (b) Interpapillary distribution. 20 0 Wk 0 Wk 8 Tacalcitol (( ’> 1 9 9 5 British Association of Dermatologists, British Immuti o f Dei Wk o Wk 8 Placebo , 13?, 6 5 3 - M 7 Wk 0 Wk B Tacalcitol Wk o Wk a Placebo •f Q /C|poj{ji?iu pun Suip/fo jo joqumu oq) jo iiopnquisïpoa y , p ip i« :)^ put? |ouipïoo ipjM •juourçnoJi oqj jo aSh^s Â\jno ira iv p^iqiqtn SI S p D jo luamjiruD&i pasrcajourç oqj ^i?qî UMoqs TOoq snq ]] oq) o} poiiïpj uouomooQqd yÇjojBSUQduioo b oq || om p poa - 0 jo 7 lu o u r ijr u o o j iu sjo:>d939jr g j X o o u i j i u a ^ p îw ro & p u i o q j, *ui>|8 iq ‘ O J J J A I I ] ■psAOid U 99q jo u si?q iih u j o u q iiM p a ic d u io o a ip ‘s o iju u o s d p o su o jo u ! si s [p o S m p A o jo jo q u m u ^ s im io is o j p o )i;,\i)u n o.) [ o i j i p j b o Q U lU Iiq iA 3A ip i2 , ) [ tu s']|n so j jo o d o a i)iv u iu u o 3 o ip u i P I° .H ) i jo O A iiis 'o d -o s B a ia re in fS s u riJ i jo Suipuiq ^i?qi aouapiAO punoj 71? jd jgissnBH ^ugmiJiîdtaoo .nï{n]poi3Jjxa otp uiojj Æqus mnpjiîo ssouiîqus *q uiiui^ia • ^ lA ip U 9ST2U 9AipB iBqi 1S3J31U] jo si "ji pgdsaj siqî U| •up[s |i;uuou i|]iM pajRduiOD piqpeuqi posiîojoui si sjpo x>. [[90 p oo np Q j si jiîin i[ 9 0 B J îu i n i s i j n s c u 4 L U 9 A ip i? m iM iuoai:|BeiJi S u y n p jo jDquinu aqi i^qi s^tuisuouiop Àprqs ^uasojd oqi ‘j3aomoh 'po^wnuRisqnsun suihuioj 3 St?uimi35n[Ssuiï.Tï jo /tyArpc âq? uo l(l UIIUI’IIA 9AIPB JO psjjs 91JÎ ‘OAÎA l/J tJI-uoiiTïzi{iqoui UITipjBD ui ot[jJ u iu ir j ia uopTLqugouoo u m io p ïD jrejrqpoH JjU T o q i jo ssu sjd u i ur Àq ssru î ‘J 9 A 9 M 0 H r i ’U m p[TîD • )u o u i)i!a ij s iq j /Cq u o q iq n d o d J iq n jp o iu jx o jo p A 3 | q îir q q j|M h uopeposs» u i paAJasqo SIÎM /Ç'IIAipB OSBUUURJtqïîSUIU) p U lî U0ISS3JdX9 UlJOtqOAU] JO 98B0J0UI u tî ‘Æprns si up[s .)| )uuos’d p o n !;x ii-i ( i uiun?iiA m s jp o V.IJ1A u iu o jj f:( i t uiumiiA fmjpn Âq po.’n mqua si /îiiAipiï o u j u m p [B 0 un i A ur uj w jo ‘s a jo js ra n p |rc o jiq r q p o B x jm u o p e a d q ii jD A o u m j s a o ira q u a [o iis o u i-[A p p \îq d s o q d puopouoiu osnom q)ïM js'npixojndouniuiui) |ouipp?3 tpiM iuomii?o.n jo s>|!)«ïm 1? jo\jw (q) pun ajojaq . iti ■V îî W - opB uosd posi’ oaom gqi ' <Æ s ■ - Æ & 4 'W ■■■■'■ ■Q$/ * ■■ ’ /• ■Vs’/ r ? - ■' 1 ■; ■ •■■■:.•.■ M ia m M ■ Y ^ v '/ c '' .><; ■. : ■■-<;i. : : v«; ■-'5•jfi!f. ■ . tïuistî]d jo uopnquisip run, •£ oanSi;! uj5[S # î '' : i’J ■ 0 ^ ■YJy/-: \ ■■• . m ^ - ;iv f f i i l É ■■ ■'• ..î - , M-/.l l ÿ ; •m r.y?:' ■ •• r n: •!-. ïê • ; l.-i I.-..-■y .\ ■■■ïj ' *> iÊ WA- •<îvî .. .iâ7:' :;v ^: • ' I-';i . -vr>- • :;•'••• ': i - : ^¡IPH •VJJ'rr' ■■■ i ¿ ï ÿ l Ÿ - '■■' \ , î \ ■ ■ ■■ ¡ î i i . - v - v j '. . ; ..î ' u <\.v< .■■ V ■>'■:<f - : '■ b - M M • (•?: Ê È È é â Ê Î. .!?* - :: î ;•, 'j;; i i :-"ÎV •: i* m m . ify iç r fy . •-•*i¿V*,m i /. ' i p p i M B M fc " '' ' .. •. i,. .-.i'j. ••if •î î '.- ■!'!J: > r; m m ¡1 Ü ü - ' i w i il «4# îl® î*; " Î l r : « .J tfï ** ,■‘ /i fc -V r .3 ' •;® v ■'■ ---------- % ' 'M ."V* '1 :.•( ï 'A .'I''*• .,i. • . ■ 'î,'. V- : < ï & '■ l. • 'J •«'î'.'-.l'.'/V/i1.*V'i'*/ ; • fïj : ',1: ■yf ■■.’■.h l■ i-:i vVr'Vvvj/i •' <"<: ; • - • V 'r r - v .V Î M i'i tt V - - .':- : b /S W W & W $ w ; .;, ■ y.i- m m m m i.-u l,:'v!j î-;V\ i • ' ' 1•' : ' î - ' • •:' ' "• "• : *'■1' :v> ••’• ' M y w âim m Ar .-•.:■::yr ;• :;•• ! i : : - :v ï^ j ■ m ■ ■ ï : ï ï é \ ï <. ■■?/...■ *•:*: . 1I i- .11 W M i/- - ** •,.i ' 'M! *1. '*,*1 lÜ ••Viv :";:;.ï.iiV . « /,V . ?.. I lî. il . : .> • • ..: V. • :,'.' '. : :: i •• : • i : . i' .ü. ' :-V' ".V ! : : ..¿-y;:- . >,: . •ivr.' > ••. J' : • r™ i :.r:‘ ^ 'J- vî : • : ; ir, s-.aUC^:.<: ■’■/■•'}.’■L-■ : î-M. .'-î;' '• • ... ' v - ■ y ■ . . 7- • ss . • . î,. '..-î. . \ S :■!lUJ.SfÆ ï M {:f- ■:.•••y/si^. •Vf/:'. V ; ::v , / : v . ■'•r./ i ■ ^ --r.y ,-v; *• ' 1 :¥ : % 1 , •- » l ï f 1 ‘ •Î‘r :■ & A ,ïV iss.- ............••:.;%•!:• ■.V;-: v;.1.1,'v' ■■■ m •• • : :. ; .V...--; V-ih:A.'- ■■: •i lllü r'•: >':; ill '■■'SI' ¡Ml M' ■ ! >-i I'*•0 •*-'if.'.-* 1. - - - ■v - :•■- -■: ■< ) r‘i-: • li'. -•iVU:; : i :; '' i p p i | p ^ æ ,^p«#siis^ipwii * -v . . -t^r. ■", : <Î< V' i 1 :ri/' •r* 11 ;'. :. y i l f|^‘ ■.i'-S.'. 1'.T' • . :.-.: ;..:-.'.-.:/'V -:v ^ :.'.V v - j fà ïm w Æ ié iïM & k 'V/;.: ......Ÿ ; . . 0 ■ : = %; ! IS IfS ilil 'V-: - • iiiîP lI# •v t ■Vv. : W ;: i:.I£r.':/ ,‘^ÎSÏViiy:5ks"^ < -: V:--. . '-'v.: .V 1 % . ït^//lAüit ^ - 4-ipwWStf^ é ï v . i w ,- ih v -, v >iO:i VtmUfi-W' ■• ••-v •*Ji. ' V.i* ••;.»: .1; ! ^-.Vx ÿ% i r • : » r aoN aaN O dsaH H O Q 8S9 D e p a r tm e n t o f D e rm a to lo g y , U n iv e r s ity H ospital N ijm eg en PO Box 9 101, M.J.P.GlïRRITSKN P .E .J.van E rp Treatment of recurrent aphthous stomatitis with pentoxifylline P . C . M . v a n de K urkhof 6 5 0 0 H B N ijm e g e n , The N e th e rla n d s References 1 W att I'M. Involucrin and other markers of keratlnocytc terminal differentiation. ƒ Invest Dermatol 1983; 81 (Suppl.): 1 0 0 —3s. 2 M urphy GF, Flynn TC, Rice RII, Pinkus GS. Involucrin expression in normal and neoplastic hu m an skin: a m arker for keratinocyte dilTerentiation. J Invest Dermatol 1984: 82: 4 5 3 - 7 . i Kanitakis J, Ramirez-Bosca A, Reano A et a l Filaggrin expression in normal and pathological skin. Virchows Archiv A Pathol Anal Histopathol 1988; 412: 3 7 5 - 8 2 . 4 YalTe MB, M urthy S, Eckert RL. Evidence th at involucrin is a covalently linked constituent of highly purified cultured keratinocyte cornified envelopes, ƒ Invest Dermatol 1993; 100: 3 -9 . 5 Bsmann J, Voorhees JJ, Fisher GJ. Increased membrane-associated transglutam inase activity in psoriasis. Biochem Res Commun 1989: 164: 2 1 9 - 2 4 . 6 Gerritsen MJP, Rule I-IFC, van Vlijmen-Willems IMJJ et al. Topical treatm ent with 1,25 dihydroxyvitamin D3: a cell biological study. B r J Dermatol 1993; 128: 6 6 6 - 7 3 . 7 Binderup L, Bramm E. Effects of a novel vitamin D j analogue MC 903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 1988; 37: 8 8 9 -9 5 . 8 Kragballe K, Wildfang IL. Calcipotriol MC 903, a novel vitamin D 5 analogue, stimulates terminal differentiation and inhibits prolif eration of cultured h u m an keratinocytes. Arch Dermatol Res 1990: 2 8 2 : 1 6 4 -7 . 9 M atsunaga T, Yamamoto M, Mimura II et al. .1,24 (R) dihydroxy vitamin Dj, a novel active form of vitam in I)5 with high activity for inducing epidermal dilTerentiation but decreased hypercalcemic activity. J Dermatol 1990; 17: 1 3 5 -4 2 . 10 Gerritsen MJP, Boezeman JBM, van Vlijmen-Willems IM]f. van de Kerkhof PCM. The effect of tacalcitol (1,24 (OH)) 0 j ) on cutaneous inllammation, epidermal proliferation and keratinization in psoriasis, a placebo-controlled double-blind study. Br J D erm atol} 994; 131: 5 7 - 6 3 . 11 Phillips MA, Stewart BE, Qin Q et al. Primary structure of keratinocyte transglutaminase. Proc Natl Acad Sei USA 1990; 87: 9 3 3 3 -7 . 12 Schmidt R, Michel S, Shroot B, Reichert U. Transglutam inases in norm al and transformed h u m an keratinocytes in culture. ƒ Invest Dermatol 1988; 90: 4 7 5 - 9 . 13 Michel S, Courseaux A, Miguel C et al. Determination of retinoid activity by an enzyme-linked im m unosorbent assay. Anal Biochem 1991; 192: 2 3 2 - 6 . 14 v an de Kerkhof PCM. Common pathw ays for epidermal growth and inflammation and their relevance in the pathogenesis of psoriasis. Int J Dermatol 1991; 30: 7 5 5 - 6 2 . 15 Bittiner B, Bleehen SS, MacNeil S. l a , 2 5 (OH)2 vitam in D, increases intracellular calcium in h u m a n keratinocytes. Br ƒ Dermatol 1991; 124: 2 3 0 - 5 . 16 Haussier MR, Donaldsen CA, Kelly MA. Functions and m echanism of action of the 1,25-dihydroxy-vitamin D 5 receptor. In: Vitamin D: a Chemical, Biochemical and Clinical Update (Norman AW, Schaefer K, Grigoleit 1-I-G, eds). Berlin: de Gruyter, 1985; 8 3 - 9 2 . 17 Bauer FW. Cell kinetics. In: Textbook of Psoriasis (Mier PD, van de Kerkhof PCM, eds). Edinburgh: Churchill Livingstone, 1986; 100 - 12 . Sir, Recurrent aphthous stomatitis (RAS) is one of the most common diseases affecting the oral mucosa. Many drugs, including analgesics, antibiotics, topical and systemic corti costeroids, dapsone, colchicine and thalidomide, have been used to relieve pain and to reduce the frequency of relapse. They are not always effective, and side-effects are a complicating factor. Pentoxifylline (PTX) is a methylxanthine derivative with haemorrheologlcal and antithrombotic prop erties.2 Recent experimental arid clinical observations have demonstrated that PTX also has immunomodulating and anti inflammatory activities,3 which seem to be related, at least in part, to the inhibitory effect of PTX on tumour necrosis factor (TNF)-alpha production.4 Thalidomide, which is one of the treatments of choice for severe RAS,15 also inhibits TNF-alpha production/1This observation led us to speculate that PTX and thalidomide could share certain therapeutic effects, such as , we the prevention of RAS.7 six pi with RAS who were successfully treated with PTX. Oral therapy with PTX (400 mg tw o-three times daily) suppressed the recurrence of aphthae in five patients, and led to a reduction in the number and duration of ulcers, with symptomatic improvement, in one patient.8 We now report 22 additional cases. Twenty-two patients (14 women and eight men) between 19 and 75 years of age (mean 34 years), were enrolled in this open study. All the patients were diagnosed as having minor RAS, and had a disease duration of 2 -8 years (mean 3*5 years). They all had multiple oral aphthous ulcers lasted for 7 -1 5 days, and experienced recurrences at every 2 months. Seventeen patients had neither clinical nor analytical evidence of any underlying systemic or cutaneous disease. The remaining five patients suffered from itis (which was treated with low-dose oral corticosteroids nonand mesalazine), rheumatoid arthritis (treated steroidal anti-inflammatory drugs), subacute cutaneous lupus erythematosus (treated with topical corticosteroids and sunscreening cream), anorexia nervosa and Parkinson's disease. All the patients received oral therapy with PTX at a dose of 400 mg three times daily. Patients were studied monthly for a 6-month oerlod. Two the drug was month. The drug was well tolerated by the remaining 20 p a c\ s. No the course of treatment were observed in 11 patients (50%), including those cases with anorexia nervosa, ulcerative md cutaneous lupus erythematosus. Six patients (27%) showed recurrence of the lesions during the period of the study, but there was a reduction in the number and duration of ulcers, as well as in the pain and difficulty with eating. Recurrence of aphthous ulcers without symptomatic improvement was I The present study, and our that continuous PTX treatment can or reduce its severity, In most patients. In addition, © 1995 British Association of Dermatologists, British Journal of Dermatology, 133, 6 5 3 - 6 6 7
© Copyright 2024 ExpyDoc